Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Covid-19 Impact: NPPA...

    Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-02-28T16:26:06+05:30  |  Updated On 28 Feb 2020 4:26 PM IST
    Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

    New Delhi: In the light of coronavirus outbreak worldwide, the apex drug regulator National Pharmaceutical Pricing Authority (NPPA) has identified 58 significant APIs for monitoring of their availability to prevent any shortage of drugs in India and to take preventive measures over illegal hoarding and black-marketing in the country.

    For the same Rajesh K. Agrawal, Director (M&E), has recently directed all importers of APIs/manufacturers of formulations and APIs/ stockists to submit information about these drugs in the prescribed format.

    The move comes in line with the recent direction of the NPPA to all the state drug regulators to ensure that that there is no shortage of drugs due to black-marketing and hoarding is their specified area.

    "The outbreak of Coronavirus (COVID-19) in China which affects the availability of key Active Pharmaceutical Ingredients (APIs) / Key Starting Materials (KSMs) in India. As part of public health preparedness in respect of APIs / Intermediates /KSMs which are imported from China, a Committee was constituted by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers vide OM No. 35022/4/2020-Policy dated 06.02.2020.," the memorandum statedx

    " Accordingly, in pursuance of the powers laid down under Para 29 of DPCO, 2013, all importers of APIs/manufacturers of formulations and APIs/ stockists are directed to submit the information in the prescribed formats (enclosed) (Form-A for merchant importers and Form-B for Indigenous manufacturers/stockists), duly signed by the authorised person.The above information, as on 29th Feb, 2020, shall be submitted before 3rd March, 2020 along with soft copy in excel format of the same at the following email Ids manjesh.porwal@gov.in, dir-me.nppa@nic.in.", the memorandum further directed

    The memorandum was sent to various State Drug Controllers (SDCs), to ensure the compliance fo the order.

    A copy was also sent to organisations such as IPA, BDMA, OPPI, IDMA, FICCI, CII, FOPE for wider dissemination or the order asking them to ensure compliance of the same

    To check out the full list of 58 APIs click on the following link

    https://business.medicaldialogues.in/pdf_upload/pdf_upload-124885.pdf

    To check out the prescribed format for importers, click on the following link

    https://business.medicaldialogues.in/pdf_upload/pdf_upload-124886.pdf

    To check out the prescribed format for Indigenous manufacturers/stockists, click on the following link

    https://business.medicaldialogues.in/pdf_upload/pdf_upload-124888.pdf

    Read also:Ensure that there is no hoarding, blackmarketing of medicines: NPPA chief tells states on Covid-19 outbreak

    nppacoronaviruscovid-19apidrugs-shortagerajesh-k.-agrawal

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok